Printer Friendly

Articles from M2 Pharma (April 26, 2019)

1-16 out of 16 article(s)
Title Author Type Words
Acutus Medical announces CE mark for new contact mapping software for cardiac ablation treatment. 242
Aptorum Group establishes Smart Pharma subsidiary. 132
Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns USD 25m Milestone Payment from Janssen. 409
Bausch Health Companies Inc wins US FDA approval for DUOBRII Lotion 0.01%/0.045% for treating plaque psoriasis in adults. 247
CANbridge Pharmaceuticals announces new executive appointment. 194
Cavion to Present Results of Phase 2 Essential Tremor Clinical Trial in Platform Presentation at the American Academy of Neurology. 353
CSL Behring awarded US FDA approval for new vial sizes of ZEMAIRA for treating Alpha 1. 260
Gencove awarded Phase I SBIR grant to validate polygenic risk score estimation from low-pass sequencing. 195
Kite plans for new Maryland facility. 204
PerkinElmer achieves higher GAAP earnings per share of USD0.32 for Q1 2019. 182
Precigen to open new manufacturing facility. 183
Stealth BioTherapeutics concludes patient enrolment in PMM study. 216
Symic Bio finalises USD11m investment. 117
Teva Pharmaceutical to halt fremanezumab's ENFORCE clinical development program. 150
US Bioservices Selected by Biocodex SAS to Exclusively Dispense Diacomit. 436
X4 Pharmaceuticals Names Kelley as Chief Medical Officer. 375

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters